



# Journal of Medical Sciences

ISSN 1682-4474

**science**  
alert

**ANSI***net*  
an open access publisher  
<http://ansinet.com>

---

---

# Research Paper

---

---

J. Med. Sci., 2 (4): 198-201  
July-August, 2002

*JMS (ISSN 1682-4474) is an International, peer-reviewed scientific journal that publish original article in experimental & clinical medicine and related disciplines such as molecular biology, biochemistry, genetics, biophysics, bio-and medical technology. JMS is issued six times per year on paper and in electronic format.*

*For further information about this article or if you need reprints, please contact:*

J. A. Khanam  
Department of Biochemistry,  
University of Rajshahi,  
Rajshahi-6205 Bangladesh

e-mail: masud1975bd@yahoo.com

## ***In vitro* Antibacterial Activity of 2, 2-Diamino-1-Azavinyl Aminoamide**

J. A. Khanam, M. Akhtaruzzaman,  
A. Y. K. M. Masud Rana and M. Shajahan

A new compound 2,2-diamino-1-azavinyl aminoamide was synthesized by the reaction of hydrazine hydrate and urea. It was screened against eleven bacteria for its antibacterial activity. At dose  $30 \mu\text{g disc}^{-1}$  tested compound shows diameter of zone of inhibition within the range 12-24 mm against all of the tested bacteria which was found to be larger range as compared to kanamycin (27-36 mm) at the same dose. Minimum inhibitory concentration was obtained against *Shigella dysenteriae*, *Salmonella typhi* and *Sarcina lutea* with in the range of  $8-16 \mu\text{g ml}^{-1}$ . The brine shrimp lethality of the compound was found to be  $8.12 \mu\text{g ml}^{-1}$ . The tested compound possesses a pronounced cytotoxic effect as observed from mortality rate of brine shrimp noplili but the compound ( $10 \text{ mg kg}^{-1}$ ) had no major toxic effect on hematological parameters in mice. In conclusion, the tested compound, 2,2-diamino-1-azavinyl aminoamide may be considered as a new one having potential antibacterial activity with less toxic effect on hematological parameters.

**Key words:** Antibacterial activity, 2, 2-Diamino-1-azavinyl aminoamide  
hematology

## Introduction

The compounds containing the semicarbazone functional group ( $-C-NH-N=C<$ ) possess antineoplastic and antiviral activities (Blanj *et al.*, 1968; Patel *et al.*, 1993; Brooth *et al.*, 1971). Semicarbazones are typically excellent coordination agents for transition elements such as iron, cobalt, nickel, copper, zinc and manganese (French and Blanz, 1966 and Michaud *et al.*, 1968) which are present in biological systems. This property enables semicarbazones to chelate the iron, which is a cofactor in the ribonucleotide diphosphate reductase enzyme system. It limits the availability of deoxyribonucleotides and inhibits the synthesis of DNA (Agrawal *et al.*, 1970; Moore *et al.*, 1970 and 1971).

In this research paper, 2,2-diamino-1-azavinyl aminoamide, a new compound containing the semicarbazone functional group has been synthesized for the first time. Antibacterial activity of this compound has been studied. Cytotoxic characteristics and effect of this compound on hematological parameters in mice have also been evaluated.

## Materials and Methods

**Synthesis of 2,2-diamino-1-azavinyl aminoamide:** Urea (24 gm) and hydrazine hydrate (10 gm) were dissolved in 25 ml distilled water and refluxed for 8 hour. On cooling to 0 °C 2,2-diamino-1-azavinyl aminoamide (reactions are shown in Fig. 1) crystallized out. This compound was purified by repeatedly washing with alcohol followed by dissolving in water and recrystallized by alcohol.

Kanamycin was purchased from BDH. All other chemicals were of reagent grade. Tested bacteria were collected from the Department of Pharmacy, University of Dhaka, Bangladesh.




Fig.1: Synthesis of 2,2-diamino-1-azavinyl aminoamide

**Antibacterial screening:** Eleven bacteria (four gram positive and seven gram negative) were selected for this study. Nutrient agar was used as bacteriological media. Antibacterial potency of 2,2-diamino-1-azavinyl aminoamide was measured against all the test microorganisms according to the standard disc diffusion method (Beur *et al.*, 1966) where air dried sterile Whatmann filter paper discs (6 mm diameter) with centers of at least 24 mm apart were deposited on nutrient agar plates using aseptic technique. Bacterial inoculum containing approximately,  $10^4$ - $10^6$  colony forming units (CFU) per ml were spread on the surface of nutrient agar. The test compound at doses of (30, 50 and  $100 \mu\text{g disc}^{-1}$ ) were added into three discs. The fourth disc was supplemented with reference drug, kanamycin at dose  $30 \mu\text{g disc}^{-1}$  serving as a positive control. The plates were incubated immediately at 37 °C for 14-19 hrs. Activity was determined by measuring the diameter of zones (mm) showing complete inhibition. Growth of inhibition was calculated with reference to positive control.

**Minimum inhibitory concentration (MIC):** The minimum inhibitory concentration of 2,2-diamino-1-azavinyl aminoamide

was determined against all of the tested organisms by serial dilution technique (Javetz *et al.*, 1980). The media used in this respect were nutrient broth media. Decreasing concentration of the test compound was prepared in serial two-fold dilution using the stock solution ( $1.024 \text{ mg ml}^{-1}$ ). Bacterial suspension ( $10 \mu\text{l}$ ) containing  $10^7$  cells  $\text{ml}^{-1}$  was inoculated into all of the tubes. After incubation for 24 hrs at 37 °C the test tube with no visible growth of the microorganism was taken to represent the MIC of test sample in  $\mu\text{g ml}^{-1}$ .

**Brine shrimp lethality bioassay:** Twelve vials were taken (two vials for each concentration) for this study. Seawater (5 ml) was given to each of the vials. The test compound at doses of 5, 10, 20, 40 and  $80 \mu\text{g ml}^{-1}$  were transferred to 10 vials and two vials were used as control. With the help of pasteur pipette 10 living shrimps were inoculated into each of the vials. After 24 hours, vials were observed and numbers of survival noplui in each vial were counted (Atta-ur-Rahman *et al.*, 1999 and Meye *et al.*, 1982).

**LD<sub>50</sub> determination:** To get the LD<sub>50</sub> dose of 2,2-diamino-1-azavinyl aminoamide, similar experiment was performed with Swiss Albino mice as described by Litehifield and Wilcoxon (1949). The drug solution in water was administered in different dose (i.p.) in male mice. LD<sub>50</sub> was evaluated by recording mortality upto 24 hrs.

**Hematological studies:** For this study three groups of Swiss Albino mice (n=4) were taken. Two groups of mice were treated with 2,2-diamino-1-azavinyl aminoamide at doses 10 and  $20 \text{ mg kg}^{-1}$  i.p. for 10 consecutive days and third group of mice was considered as control. Blood was collected from individual mice for experiment on day 12 of treatment. Total counts of white blood cells (WBC) and red blood cells (RBC) as well as hemoglobin (Hb) content were determined by standard method (Rusia and Sood, 1988) using cell diluting fluids and a hemocytometer. The differential count was carried out with Wright stain.

**Statistical analysis:** The student-t test (Ghosh, 1984) was used for the statistical analysis of the results. P values <0.05 were considered as significant.

## Results

**Characterization of 2,2-diamino-1-azavinyl aminoamide:** Melting point of 2,2-diamino-1-azavinyl aminoamide was found to be 195-198 °C. The elemental analysis was done with Perken Elmer 2400 Series II CHNS/O analyzer (USA). From elemental analysis, values found C: 20.21; N: 59.61; H: 5.61% as against the calculated C: 20.51; N: 59.82; H: 5.9%. Infrared spectra were recorded in KBr matrix on Parkin-Elmer Spectrophotometer in the region  $4000$ - $400 \text{ cm}^{-1}$ . IR spectrum of the test compound exhibited peaks at  $3400$  and  $3200 \text{ cm}^{-1}$  indicated the presence of primary and secondary amines. Characteristic carbonyl group ( $>C=O$ ) showed absorption band at  $1500 \text{ cm}^{-1}$ . Mass spectra was measured using chemical ionization (CI)/ Methane process. Base peak of the test compound was 117 (Fig. 2) which supports the molecular structure of 2,2-diamino-1-azavinyl aminoamide ( $\text{NH}_2\text{-CO-NH.N=C(NH}_2)_2$ )

**Antibacterial activity:** Antibacterial activity of 2,2-diamino-1-azavinyl aminoamide was measured using doses 30, 50 and  $100 \mu\text{g disc}^{-1}$ . All the gram positive and gram negative bacteria showed remarkable sensitivity to the test compound at all doses used, which were compared with standard antibacterial agent kanamycin ( $30 \mu\text{g disc}^{-1}$ ) (Table 1). The test compound at dose ( $30 \mu\text{g disc}^{-1}$ ) showed the lowest diameter of zone of inhibition (12 mm) against *Shigella dysenteriae* where as 28 mm diameter was observed with kanamycin at the same dose. The diameter of zone of inhibition with kanamycin (at dose  $30 \mu\text{g disc}^{-1}$ ) against *Bacillus subtilis*, *Bacillus megatarium*, *Sarcina lutea* and *Salmonella typhi* were found to be 29, 36, 33 and 29 mm respectively, where as the test compound ( $30 \mu\text{g disc}^{-1}$ ) showed only 19 mm against these bacteria. The tested compound ( $30 \mu\text{g disc}^{-1}$ ) showed the diameter of zone of inhibition 21, 24, 20, 21 and 20 mm against *Bacillus cereus*, *Escherichia coli*, *Shigella sonni*,

Khanam *et al.*: Antibacterial activity of 2,2-diamino-1-azavinyl aminoamide

Table 1: Antibacterial activity of 2,2-diamino-1-azavinyl aminoamide

Test bacteria	Diameter of zone of inhibition (mm) after 24hr of incubation			
	2,2-Diamino-1-azavinyl aminoamide			Kanamycin
	30 $\mu\text{g disc}^{-1}$	50 $\mu\text{g disc}^{-1}$	100 $\mu\text{g disc}^{-1}$	30 $\mu\text{g disc}^{-1}$
<b>Gram positive</b>				
<i>Bacillus cereus</i>	21	25	30	28
<i>Bacillus subtilis</i>	19	21	30	29
<i>Bacillus megaterium</i>	19	28	33	36
<i>Staphylococcus aureus</i>	21	30	32	27
<b>Gram negative</b>				
<i>Escherichia Coli</i>	24	28	33	29
<i>Shigella sonnei</i>	20	26	32	31
<i>Shigella shiga</i>	21	31	33	28
<i>Shigella boydii</i>	20	26	33	30
<i>Shigella dysenteriae</i>	12	15	24	28
<i>Sarcina lutea</i>	19	30	33	33
<i>Salmonella typhi</i>	19	30	33	29

Table 2: Minimum inhibitory concentration of 2,2-diamino-1-azavinyl aminoamide against gram positive and gram negative bacteria

Test bacteria	Minimum inhibitory concentration of 2,2-diamino-1-azavinyl aminoamide ( $\mu\text{g ml}^{-1}$ )									
	512	256	128	64	32	16	8	4	2	1
<b>Gram positive</b>										
<i>Bacillus subtilis</i>	-	-	-	+	+	+	+	+	+	+
<i>Bacillus cereus</i>	-	-	-	-	+	+	+	+	+	+
<i>Bacillus megaterium</i>	-	-	-	+	+	+	+	+	+	+
<i>Staphylococcus aureus</i>	-	-	-	+	+	+	+	+	+	+
<b>Gram negative</b>										
<i>Shigella dysenteriae</i>	-	-	-	-	-	-	-	+	+	+
<i>Shigella boydii</i>	-	-	-	-	+	+	+	+	+	+
<i>Shigella sonnei</i>	-	-	-	-	-	+	+	+	+	+
<i>Escherichia Coli</i>	-	-	-	-	-	+	+	+	+	+
<i>Shigella shiga</i>	-	-	-	-	-	+	+	+	+	+
<i>Sarcina lutea</i>	-	-	-	-	-	-	+	+	+	+
<i>Salmonella typhi</i>	-	-	-	-	-	-	+	+	+	+

(+) = Growth, (-) = No growth




Fig. 2: Mass spectrum of the compound 2,2-diamino-1-azavinyl aminoamide

*Shigella shiga*, *Shigella boydii* respectively. These diameters of zones were found to be lower than those obtained with kanamycin (30  $\mu\text{g disc}^{-1}$ ).

**Minimum inhibitory concentration:** Minimum inhibitory concentration of 2,2-diamino-1-azavinyl aminoamide was found to be 8  $\mu\text{g ml}^{-1}$  against *Shigella dysenteriae* ( $10^7$  cells  $\text{ml}^{-1}$ ) [Table 2] and it was found to be 16  $\mu\text{g ml}^{-1}$  against *Sarcina lutea* and *Salmonella typhi* ( $10^7$  cells  $\text{ml}^{-1}$ ) and 32  $\mu\text{g ml}^{-1}$  against *Shigella sonnei* and *Escherichia coli*, *Shigella shiga*.




Fig. 3: Effect of 2,2-diamino-1-azavinyl aminoamide on brine shrimp mortality  
Conc = Concentration of 2,2-diamino-1-azavinyl aminoamide

Minimum inhibitory concentration of the test compound was found to be 64  $\mu\text{g ml}^{-1}$  against *Bacillus cereus* and *Shigella boydii* and it was 128  $\mu\text{g ml}^{-1}$  against *Staphylococcus aureus*, *Bacillus subtilis* and *Bacillus megaterium*.

**Brine shrimp lethality bioassay:** To find out the cytotoxic effect of 2,2-diamino-1-azavinyl aminoamide, median lethal concentration of brine shrimp ( $\text{LC}_{50}$ ) was measured and it was found to be 8.12  $\mu\text{g ml}^{-1}$  (Fig 3). A plot of percent mortality versus log concentration

Table 3: Effect of 2,2-diamino-1-azavinyl aminoamide on hematological parameters in mice

Parameters	Normal mice (control)	2,2-Diamino-1-azavinyl aminoamide (10 mg kg <sup>-1</sup> )	2,2-Diamino-1-azavinyl aminoamide (20 mg kg <sup>-1</sup> )
Hb (gm dl <sup>-1</sup> )	14.50 ± 0.54	13.33 ± 0.25	10.50 ± 0.28**
RBC (× 10 <sup>9</sup> ml <sup>-1</sup> )	8.33 ± 0.45	6.60 ± 0.98	5.20 ± 0.34**
WBC (× 10 <sup>6</sup> ml <sup>-1</sup> )	7.00 ± 0.27	9.00 ± 1.60	10.67 ± 1.00**
Lymphocyte (%)	70.00 ± 1.80	52.00 ± 3.00*	50.00 ± 2.00**
Neutrophil (%)	28.00 ± 2.70	46.00 ± 2.05**	47.50 ± 2.50**
Monocyte (%)	2.00 ± 0.54	2.00 ± 0.28	2.00 ± 0.29

Results are Mean ± SEM \* : P < 0.02, \*\* : P < 0.001

produced an approximate linear correlation between them (Fig. 3).

**LD<sub>50</sub> determination:** Mice treated with 2,2-diamino-1-azavinyl aminoamide (150 mg kg<sup>-1</sup> i.p.) did not show any toxic side effects regarding body weight of mice.

**Hematological studies:** At dose of 10 mg kg<sup>-1</sup> i.p. show no significant change in hemoglobin, RBC and WBC content in mice blood (Table 3). Lymphocyte and neutrophil percent were found to be changed to some extent. At dose 20 mg kg<sup>-1</sup> i.p. all of the hematological parameters were found to be altered significantly from the normal values.

## Discussion

Study of a new compound as medicine the use of screening techniques, which can indicate its potential pharmaceutical action, is an absolute requirement. The primary bioassay screenings such as antimicrobial assays, brine shrimp lethality assay have been studied accordingly. Antibacterial activity of 2,2-diamino-1-azavinyl aminoamide was measured against some gram positive and gram negative bacteria, which are responsible for large number of human, animal and plants diseases. The test compound shows higher antibacterial activity than the known drug kanamycin. At dose 30 µg disc<sup>-1</sup> tested compound shows diameter of zone of inhibition within the range 12-24 mm against all of the bacteria, which was found to be larger range as compared to kanamycin (27-36 mm) at the same dose. Minimum inhibitory concentration was obtained against *Shigella dysenteriae*, *Salmonella typhi* and *Sarcina lutea*. Low value of median lethal concentration (LC<sub>50</sub>) indicates the cytotoxic effect of the tested compound. There was a positive correlation between brine shrimp lethality and cytotoxicity of the compound. In this bioassay the mortality rate of brine shrimp was found to be increased with the increase of concentration of the tested compound. The test compound had no major toxic effect on hematological parameters at low dose. Considering all the above points, the compound 2,2-diamino-1-azavinyl aminoamide may be considered as a new one having potential antibacterial activity with less toxic effect on hematological parameters. The results suggest further extensive work on the test compound *in vivo*.

## Acknowledgment

One of the author (J. A. Khanam) is thankful to Dr. M. A. Jalil Miah, Post Doctoral Fellow, Department of Chemistry, University of Florida, U.S.A. for providing mass spectrum of 2,2-diamino-1-azavinyl aminoamide.

## References

- Agrawal, K.C., B.A. Booth, R.L. Michaud, A.C. Sartorelli and E.C. Moore, 1970. Comparative studies on the action of 5-hydroxy-2-formylpyridine thiosemicarbazone and its selenosemicarbazone and semicarbazone analogs. Proc. Am. Assoc. Cancer Res., pp: 11: 2.
- Atta-ur-Rahman, M.I.C. and W.J. Thomson, 1999. Manual of bioassay techniques for natural product research. Howard Academic Press. Amsterdam, pp: 12-22.
- Blanaj, E.J. and F.A. Jr. French, 1968. The carcinostatic activity of 5-hydroxy-2-formyl pyridine thiosemicarbazone. Cancer Res., 28: 2419-2422.
- Beur, A.W., W.M. Kirby M., J.C. Sherris and M. Truck, 1966. Antibiotic susceptibility testing by a standardised single disc method. Am. J. Clin. Path., 45: 493-497.
- Brooth, B.A., E.C. Moore and A.C. Sartorelli, 1971. Metabolic effects of some tumor inhibitory pyridinecarboxyaldehyde thiosemicarbazones. Cancer Res., 31: 228-234.
- French, F.A. and E.J. Jr. Blanz, 1966. The carcinostatic activity of α (N) heterocyclic carboxy aldehyde thiosemicarbazone II, 3-hydroxy pyridine-2-carboxyaldehyde thiosemicarbazone. Cancer Res., 26: 1638-1640.
- Ghosh, M.N., 1984. Fundamentals of Experimental Pharmacology. Second Edition. Scientific Book Agency, Calcutta, 177-211.
- Jawetz, E., J.L. Melnick and E.A. Adelberg, 1980. Review of Medical Microbiology. Lange Medical Publications, California. 14<sup>th</sup> edition, pp: 123-124.
- Litchfield, J.T. and F.A. Wilcoxon, 1949. Simplified method of evaluating dose effects experiments. J. Pharmacol. Exp. Ther., 96: 99-102.
- Michaud, R.L. and A.C. Sartorelli, 1968. Antitumor and metal coordinating activities of the thiosemicarbazone, Semicarbazone and Guanylylhydrazone of 1-formyl-isoquinoline. Abstract of the American Chemical Society Meeting. San Francisco, California, 54(SIR).
- Moore, E.C., M.S. Zedeck, K.C. Agrawal and A.C. Sartorelli, 1970. The inhibition of ribonucleotide diphosphate reductase by 1-formyl-isoquinoline thiosemicarbazone and related compounds. Biochemistry, 9: 4492-4498.
- Moore, E.C., B.A. Booth and A.C. Sartorelli, 1971. Inhibition of deoxyribonucleotide synthesis by pyridine carboxyaldehyde thiosemicarbazones. Cancer Res., 31: 235-238.
- Meye, B.N., N.R. Ferrigini, J.E. Putnum, L.B. Jacobsen, D.E. Nicholas and J.L. McLaughlin, 1982. Brine shrimp: A convenient general bioassay for active constituents, Planta Medica, 45: 31-34.
- Patel, P.S., R.M. Ray and M.M. Patel, 1993. Synthesis, characterization and antimicrobial activity of metal chelates derived from α-oximino-acetoacetate-*o/p*-toluidide thiosemicarbazone. J. Indian Chem. Soc., 70: 99-102.
- Rusia, V. and S.K. Sood, 1988. Routine hematological tests. In: Mukherjee K.L. (ed.). Medical Laboratory Technology. Vol 1. New Delhi: Tata McGraw-Hill Publishing Company Ltd., pp: 215-80.

MS received 19th January, 2002; accepted 17th May, 2002